Subscribe

John M. Pagel, MD, PhD

Articles by John M. Pagel, MD, PhD

Dr. Pagel on the Utility of CAR T-Cell Therapy in Relapsed/Refractory DLBCL

ByJohn M. Pagel, MD, PhD

September 22nd 2020

John M. Pagel, MD, PhD, discusses the utility of CAR T-cell therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.

Latest Updated Articles

$Dr. Pagel on the Utility of CAR T-Cell Therapy in Relapsed/Refractory DLBCL$
Dr. Pagel on the Utility of CAR T-Cell Therapy in Relapsed/Refractory DLBCL
Published: September 22nd 2020 | Updated:

Trending on CGTlive®

FDA Activity Recap: October 2025 Features New Platform Technology Designation, RDEA Pilot Program Selection, and More

© 2025 MJH Life Sciences^®

All rights reserved.